SCHEMBL5513404

SCHEMBL5513404

O=c1c2cc(F)ccc2nc2n1CCC2Br

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.46
BCHE P06276 1/20 0.46
TDO2 P48775 5/20 0.41
IDO2 Q6ZQW0 4/20 0.41
IDO1 P14902 4/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
CYP3A4 P08684 1/20 0.38
DPP4 P27487 1/20 0.38
APP P05067 2/20 0.38
RAB9A P51151 1/20 0.38
AADAT Q8N5Z0 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
JAK2 O60674 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5508182 0.92 ALDH1A1 (0.43) ACHEBCHETDO2IDO2IDO1
SCHEMBL5511623 0.89 ACHE (0.46) ACHEBCHEHRH3CYP3A4RAB9A
SCHEMBL5512927 0.84 ACHE (0.46) ACHEBCHEKDM4EALDH1A1HPGD
SCHEMBL5509462 0.83 ACHE (0.42) ACHEBCHEKDM4EALDH1A1HPGD
SCHEMBL5519038 0.82 RAB9A (0.42) ACHEBCHEALDH1A1HRH3CYP3A4
SCHEMBL5511124 0.80 ACHE (0.69) ACHEBCHEKDM4EALDH1A1HPGD
SCHEMBL5511711 0.76 ACHE (0.46) ACHEBCHEKDM4EALDH1A1HSD17B10
SCHEMBL5511808 0.76 HRH3 (0.38) ACHEBCHEKDM4EALDH1A1HPGD
SCHEMBL5511094 0.74 GAA (0.43) ACHEBCHETDO2IDO2HRH3
SCHEMBL5512717 0.73 ACHE (0.43) ACHEBCHEHRH3TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521583-B1 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-01-10 EP disclosed
US-7067519-B2 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2006-06-27 US disclosed
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates ACTELION PHARMACEUTICALS, LTD. (CH) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009852-A1 7 8 9 10-tetrahydro-6h-azepino, 6 7 8 9-tetrahydro-pyrido and 2 3-dihydro-2h-pyrrolo[2 1-b]-quinazolinone derivates HCRTR2, HCRTR1, NPY1R ACHE 2967/4885BCHE 2964/4885TDO2 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.